Human Serum With High Neutralizing Antibody Titers Against Both Zika and Dengue Virus Shows Delayed In Vitro Antibody-Dependent Enhancement of Dengue Virus Infection

Valiant, William G.; Lalani, Tahaniyat; Yun, Heather C.; Kunz, Anjali; Burgess, Timothy; Mattapallil, Joseph J.

doi:10.1093/ofid/ofy151

Cited by 12 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, observations from arbovirus surveillance in Brazil suggest a decrease in DENV circulation after the ZIKV outbreak, possibly due to DENV cross-neutralization by ZIKV antibodies [80]. Additionally, there are indications that these cross-neutralizing ZIKV antibodies can prevent DENV ADE [81, 82]. However, for DENV, it is demonstrated that the risk of severe disease depends on the titer of preexisting DENV antibodies [16].…”

Section: Enhancement Of Denv By Zikv Antibodiesmentioning

confidence: 99%

The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

et al. 2019

View full text Add to dashboard Cite

Zika virus (ZIKV) has been known for decades to circulate in Africa and Asia. However, major complications of a ZIKV infection have recently become apparent for reasons that are still not fully elucidated. One of the hypotheses for the seemingly increased pathogenicity of ZIKV is that cross-reactive dengue antibodies can enhance a ZIKV infection through the principle of antibody-dependent enhancement (ADE). Recently, ADE in ZIKV infection has been studied, but conclusive evidence for the clinical importance of this principle in a ZIKV infection is lacking. Conversely, the widespread circulation of ZIKV in dengue virus (DENV)-endemic regions raises new questions about the potential contribution of ZIKV antibodies to DENV ADE. In this review, we summarize the results of the evidence to date and elaborate on other possible detrimental effects of cross-reactive flavivirus antibodies, both for ZIKV infection and the risk of ZIKV-related congenital anomalies, DENV infection, and dengue hemorrhagic fever.

show abstract

Section: Enhancement Of Denv By Zikv Antibodiesmentioning

confidence: 99%

The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, if this threshold is not reached, neutralization fails, and infection might be enhanced. An in-depth clinical study revealed a history of vaccination against Japanese encephalitis virus two years earlier, and thus, in vitro neutralization could be mediated by antibodies binding to common epitopes among flaviviruses [43]. The use of Mexican samples was valuable because this population is from highly endemic areas of DENV; furthermore, they might have been infected by more than one DENV serotype since more than one serotype could be circulating at the same time or cyclically.…”

Section: Discussionmentioning

confidence: 99%

Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population

Montecillo-Aguado

Montes-Gómez

García‐Cordero

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

Zika virus (ZIKV), an emerging mosquito-borne flavivirus, has quickly spread in many regions around the world where dengue virus (DENV) is endemic. This represents a major health concern, given the high homology between these two viruses, which can result in cross-reactivity. The aim of this study was to determine the cross-reacting antibody response of the IgM and IgG classes against the recombinant envelope protein of ZIKV (rE-ZIKV) in sera from patients with acute-phase infection of different clinical forms of dengue, i.e., dengue fever (DF) and dengue hemorrhagic fever (DHF) (before the arrival of ZIKV in Mexico 2010), as well as acute-phase sera of ZIKV patients, together with the implications in neutralization and antibody-dependent enhancement. Differences in IgM responses were observed in a number of DF and DHF patients whose sera cross-reacted with the rE-ZIK antigen, with 42% recognition between acute-phase DHF and ZIKV but 27% recognition between DF and ZIKV. Regarding IgG antibodies, 71.5% from the DF group showed cross-reactivity to rE-ZIKV in contrast with 50% and only 25% of DHF and ZIKV serum samples, respectively, which specifically recognized the homologous antigen. The DHF group showed more enhancement of ZIKV infection of FCRγ-expressing cells compared to the DF group. Furthermore, the DHF group also showed a higher cross-neutralizing ability than that of DF. This is the first report where DF and DHF serum samples were evaluated for cross-reactivity against Zika protein and ZIKV. Furthermore, DENV serum samples cross-protect against ZIKV through neutralizing antibodies but at the same time mediate antibody-dependent enhancement in the sequential ZIKV infection.

show abstract

“…Recently, several studies have indicated that pre-existing DENV immunity mediated cross-protection against secondary ZIKV infection in mice (Pantoja et al, 2017; Wen et al, 2017). Valiant et al demonstrated that high levels of cross-neutralizing antibodies (nAbs) against DENV in ZIKV seropositive individuals could potentially reduce the enhancement of DENV infection (Valiant et al, 2018). However, some inconsistent results on the outcome of cross-reactive immune responses between DENV and ZIKV have also been reported.…”

Section: Introductionmentioning

confidence: 99%

Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine

Wang

Gao

et al. 2019

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Both Zika virus (ZIKV) and four serotypes of dengue virus (DENV1–4) are antigenically related mosquito-borne flaviviruses that co-circulate in overlapping geographic distributions. The considerable amino acid sequence homology and structural similarities between ZIKV and DENV1–4 may be responsible for the complicated immunological cross-reactivity observed for these viruses. Thus, a successful Zika vaccine needs to not only confer protection from ZIKV infection but must also be safe during secondary exposures with other flavivirus, especially DENVs. In this study, we used a Zika DNA vaccine candidate (pV-ZME) expressing the ZIKV premembrane and envelop proteins to immunize BALB/c mice and evaluated the potential cross-reactive immune responses to DENV1–4. We observed that three doses of the pV-ZME vaccine elicited the production of cross-reactive antibodies, cytokines and CD8 + T cell responses and generated cross-protection against DENV1–4. Our results demonstrate a novel approach for design and development of safe Zika and/or dengue vaccines.

show abstract

Human Serum With High Neutralizing Antibody Titers Against Both Zika and Dengue Virus Shows Delayed In Vitro Antibody-Dependent Enhancement of Dengue Virus Infection

Cited by 12 publications

References 15 publications

The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population

Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine

Contact Info

Product

Resources

About